Nabriva Therapeutics AG – (NBRV) is Omega Fund Management LLC’s 5th Largest Position

Omega Fund Management LLC continued to hold its stake in shares of Nabriva Therapeutics AG – (NASDAQ:NBRV) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,145,890 shares of the biotechnology company’s stock at the end of the first quarter. Nabriva Therapeutics AG – comprises approximately 8.9% of Omega Fund Management LLC’s holdings, making the stock its 5th largest position. Omega Fund Management LLC’s holdings in Nabriva Therapeutics AG – were worth $13,751,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in NBRV. Novo A S increased its stake in shares of Nabriva Therapeutics AG – by 108.3% in the fourth quarter. Novo A S now owns 2,326,544 shares of the biotechnology company’s stock worth $13,866,000 after buying an additional 1,209,884 shares during the period. Vivo Capital LLC increased its stake in shares of Nabriva Therapeutics AG – by 27.6% in the fourth quarter. Vivo Capital LLC now owns 4,021,559 shares of the biotechnology company’s stock worth $23,968,000 after buying an additional 869,859 shares during the period. Orbimed Advisors LLC increased its stake in shares of Nabriva Therapeutics AG – by 27.6% in the fourth quarter. Orbimed Advisors LLC now owns 1,677,940 shares of the biotechnology company’s stock worth $10,001,000 after buying an additional 362,940 shares during the period. Baker BROS. Advisors LP acquired a new stake in shares of Nabriva Therapeutics AG – during the third quarter worth about $2,468,000. Finally, Nationwide Fund Advisors acquired a new stake in shares of Nabriva Therapeutics AG – during the first quarter worth about $2,074,000. 42.86% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Nabriva Therapeutics AG - (NASDAQ:NBRV)

Shares of Nabriva Therapeutics AG – (NASDAQ:NBRV) traded down 0.20% during mid-day trading on Friday, reaching $9.79. The company’s stock had a trading volume of 11,250 shares. The firm’s market capitalization is $266.33 million. Nabriva Therapeutics AG – has a 52 week low of $3.52 and a 52 week high of $12.75. The firm has a 50-day moving average of $10.70 and a 200-day moving average of $8.42.

COPYRIGHT VIOLATION WARNING: This news story was posted by Mideast Time and is the sole property of of Mideast Time. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.mideasttime.com/nabriva-therapeutics-ag-nbrv-is-omega-fund-management-llcs-5th-largest-position/1709214.html.

NBRV has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of Nabriva Therapeutics AG – in a report on Monday, March 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Nabriva Therapeutics AG – in a report on Friday, February 17th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Nabriva Therapeutics AG – in a report on Monday, February 6th. Wedbush reaffirmed an “outperform” rating and set a $13.00 price target on shares of Nabriva Therapeutics AG – in a report on Tuesday, January 31st. Finally, Zacks Investment Research raised Nabriva Therapeutics AG – from a “sell” rating to a “hold” rating in a report on Saturday, February 4th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Nabriva Therapeutics AG – has an average rating of “Buy” and an average price target of $14.39.

In other Nabriva Therapeutics AG – news, major shareholder Hbm Healthcare Investments (Ca sold 32,831 shares of the company’s stock in a transaction dated Thursday, April 13th. The shares were sold at an average price of $11.24, for a total value of $369,020.44. Following the completion of the transaction, the insider now directly owns 2,660,689 shares of the company’s stock, valued at approximately $29,906,144.36. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 166,168 shares of company stock valued at $1,857,973.

About Nabriva Therapeutics AG –

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).

12 Month Chart for NASDAQ:NBRV

Want to see what other hedge funds are holding NBRV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nabriva Therapeutics AG – (NASDAQ:NBRV).

Receive News & Ratings for Nabriva Therapeutics AG - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG - and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.